Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00789126 · ClinicalTrials.gov registry record · Phase 1
Single and Multiple Dose Escalation Study of VX-509 in Healthy Subjects
A Phase 1 study, sponsored by Vertex Pharmaceuticals Incorporated.
- Completed
- Registry status
- Phase 1
- Development phase
- 72
- Enrollment target
NCT00789126 is a Phase 1 study that has completed, run by Vertex Pharmaceuticals Incorporated. The registered enrollment target is 72 participants.
The verdict
NCT00789126, a Phase 1 study, has completed, sponsored by Vertex Pharmaceuticals Incorporated.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 72 participants
- Enrollment target
Study Summary
Study to evaluate the safety and tolerability of single ascending doses and multiple ascending doses of VX-509 administered to healthy male and female subjects
Interventions
- DRUG VX-509
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 72 participants |
| Start Date | 2008-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00789126
The ClinicalTrials.gov registry entry for NCT00789126 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 72 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vertex Pharmaceuticals Incorporated, which has 191 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which VX-509 is the first listed.
NCT00789126 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00789126 about?
NCT00789126 is a clinical study titled "Single and Multiple Dose Escalation Study of VX-509 in Healthy Subjects". Study to evaluate the safety and tolerability of single ascending doses and multiple ascending doses of VX-509 administered to healthy male and female subjects
What is the current status of trial NCT00789126?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 72 participants. The study started on 2008-10.
What interventions are being tested in trial NCT00789126?
The interventions under investigation include: VX-509 (DRUG).
Who is sponsoring clinical trial NCT00789126?
This trial is sponsored by Vertex Pharmaceuticals Incorporated, which has 191 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.